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Abstract
Background: There is increasing interest in carrying out pre-induction cervical ripening on an
outpatient basis. However, there are concerns about the use of prostaglandins, the agents
commonly used in hospital settings for this indication, because prostaglandins induce uterine
contractions that may lead to fetal hypoxia. Indeed, in a recent study we demonstrated
abnormalities in 9% of fetal heart rate tracings performed following prostaglandin induced cervical
ripening at term. In contrast, we confirmed in the same study that isosorbide mononitrate (IMN)
(administered on an inpatient basis) was both effective in inducing cervical ripening at term, and was
associated with no associated fetal heart rate abnormalities.
Methods/design: The aim of this study is to determine whether IMN self administered by women
on an outpatient basis improves the process of induction of labour. Specifically, we hypothesise that
the use of outpatient IMN will result in a shorter inpatient stay before delivery, decreased costs to
the health service and greater maternal satisfaction with ripening and induction of labour,
compared with placebo treatment.
In the study described here (the "IMOP" study), women scheduled for induction of labour at term,
and who require pre-induction cervical ripening will be randomised to self-administer at home
either IMN 40 mg, or a placebo, each vaginally, at 48 hours, 32 hours and 16 hours before scheduled
hospital admission.
After admission to hospital, treatment will revert to the usual induction of labour protocol. We
will compare the primary outcomes of the elapsed time interval from hospital admission to vaginal
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delivery, the costs to the health service of induction of labour, and women's experience of
induction of labour in the two groups.
Discussion: This trial will provide evidence on the efficacy of outpatient IMN for pre-induction
cervical ripening at term. We will study a formulation of IMN which is cheap and widely available.
If the treatment is effective, acceptable to women, and cost effective, it could be implemented into
obstetric practice worldwide.
Trial registration: The trial has been registered on the International Standard Randomised
Controlled Trial Number Register (ISRCTN) and given the registration number ISRTN39772441.
Background
Outpatient cervical ripening
Around 20% of pregnant women undergo induction of
labour in the UK [1]. In primigravidae, the mean time
taken from induction to delivery is between 15 and 20
hours, of which up to 12 hours is spent in the cervical rip-
ening phase before labour itself starts. There is increasing
interest in carrying out cervical ripening on an outpatient
basis. Outpatient cervical ripening with prostaglandins is
associated with significantly shorter admission to delivery
times [2,3] and/or reduced health care costs [4]. Perhaps
the most significant factor in favour of outpatient cervical
ripening is women's endorsement: women were much
more likely to report high satisfaction rates with outpa-
tient compared with inpatient cervical ripening (56% v
39%, p < 0.008) [5]. However, there are concerns about
the use of prostaglandins, the agents commonly used in
hospital settings for this indication, and their use for out-
patient cervical ripening has been declared unsafe by
many authorities because of the potential for uterine con-
tractions to cause fetal hypoxia which would remain undi-
agnosed in the outpatient environment [6,7]. In a recent
study we demonstrated abnormalities in 9% of fetal heart
rate tracings performed following prostaglandin induced
cervical ripening at term. In contrast, we confirmed in the
same study that IMN (administered on an inpatient basis)
was both effective in inducing cervical ripening at term,
with no associated fetal heart rate abnormalities.
Properties of the ideal cervical ripening agent
An agent that ripened the cervix without stimulating uter-
ine activity would be the ideal cervical ripening agent for
outpatient use. We have previously demonstrated that
vaginal IMN administered on an inpatient basis is an
effective cervical ripening agent in the first trimester [8,9].
We have also shown that vaginal IMN, in the doses and at
the gestation planned here, has no clinically significant
adverse effects on either maternal or fetal haemodynamics
[10]. In our recently published "PRIM" study [11] we
found that IMN 40 mg was an effective cervical ripening
agent at term. These findings are supported by the recent
work of Ekerhovd et al, who showed that cervical resist-
ance was reduced by 50% 4 hours after treatment with 40
mg vaginal IMN at term [12]. In contrast to prostagland-
ins, nitric oxide donors inhibit rather than stimulate uter-
ine contractions, and promote rather than restrict uterine
blood flow. Thus nitric oxide donors such as IMN appear
to be the ideal cervical ripening agent for outpatient use.
Why is a trial needed now?
To our knowledge, there are no systematic reviews on out-
patient induction of labour. A Medline search using the
headings "outpatient" and "cervical ripening" and
restricted to studies in the English language on human
subjects generated 22 publications, of which 17 are rele-
vant to this application [2-4,6,7,13-26]. A search of the
Cochrane Controlled Trials Register using the same key
words did not reveal any additional studies. The majority
of published studies on outpatient cervical ripening have
used prostaglandins as the active agent. One has exam-
ined the use of Dilapan [26] and one a transcervical Foley
catheter [24].
We found no systematic reviews or studies investigating
the use of IMN for outpatient cervical ripening. Two stud-
ies have reported on the clinical use of nitric oxide donors
for cervical ripening at term on an inpatient basis. In the
first, 500 μg of the nitric oxide donor glyceryl trinitrate
was associated with fewer episodes of uterine tachysystole
compared with 3 mg PGE2 [27]. In the second 40 mg IMN
(up to three doses at 6 hour intervals) was associated with
fewer adverse events overall (including tachysystole) com-
pared with 50 μg of the prostaglandin misoprostol (up to
three doses at 6 hours intervals) [28]. In both of these
studies, whilst the nitric oxide donor was considered effec-
tive, it was less effective than the comparator prostaglan-
din on an inpatient basis.
There is increasing interest in outpatient cervical ripening.
This interest is driven at least in part by financial costs
associated with an inpatient stay in the labour ward. The
estimated cost for 24 hour labour ward stay is £500 –
£1000 [North Glasgow University Hospitals Trust Finance
department – personal communication], thus a 30%
reduction in the inpatient ripening phase of 12 hours
would be associated with a cost saving of £75 – £150 perBMC Pregnancy and Childbirth 2006, 6:25 http://www.biomedcentral.com/1471-2393/6/25
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patient. Additionally, there is a wish to "deinstitutional-
ise" the process of labour, and, where appropriate, to offer
women the opportunity to remain as an outpatient for a
longer period of time. Hofmeyer notes that information
on women's views on cervical ripening and induction of
labour are conspicuously lacking [29]. A small number of
studies, including Biem et al (2003) [5] and PRIM [11]
have provided some pilot evidence that women report
positive views about outpatient cervical ripening. Addi-
tionally, self administration of vaginal tablets on an out-
patient basis is acceptable to women in other clinical
situations [30]. There is as yet no research evidence on the
views of women who have experienced IMN induced cer-
vical ripening in an outpatient setting, and women's
acceptance of the novel situation of "pre-induction cervi-
cal ripening induction at home" is vital to its ultimate suc-
cess. IMOP will address not only the clinical efficacy of
outpatient administration of IMN for pre-induction cervi-
cal ripening, but also the economics of this strategy
together with an assessment of women's views and expe-
riences.
We believe that IMN may be the most appropriate pre-
induction cervical ripening agent for outpatient use, since
its uterine relaxant properties (in contrast to the uterine
stimulant effects of prostaglandins) obviate the main rea-
son for continuous fetal heart rate monitoring. A trial of
outpatient IMN is particularly timely, because we have
recently demonstrated the efficacy, safety and patient
acceptability of inpatient cervical ripening with IMN in
the PRIM study. In the PRIM study cervical ripening with
IMN (two doses of 40 mg 16 hours apart) was compared
on an inpatient basis with the agent conventionally used
in the Princess Royal Maternity, Glasgow (prostaglandin
gel, two doses of 2 mg, 16 hours apart). Briefly, the use of
IMN as a cervical ripening agent was significantly more
acceptable to women than the prostaglandin used as an
alternative (mean [SD] visual analogue score of maternal
satisfaction with treatment of 7.03 [2.71] with IMN com-
pared with 5.79 [3.07] with prostaglandin, p < 0.0001).
We also confirmed that inpatient treatment with IMN was
not associated with events that would preclude outpatient
use. The PRIM study evaluated the inpatient use of IMN
for cervical ripening. However, we believe that it is as out-
patient therapy where the effects of IMN may be the most
significant advance in cervical ripening. The "IMOP"
study described here will be the first to evaluate the use of
IMN in this setting. We consider that it is particularly
timely to embark on such a trial now, given that data from
the PRIM study suggests that outpatient use of IMN is
likely to be safe and effective.
Methods and trial design
Aims of the trial
The aim of this trial is to test the hypothesis that IMN, 40
mg every 16 hours to a total of three doses improves the
process of induction of labour. Specifically we aim to test
the hypotheses that outpatient pre-induction cervical rip-
ening with IMN:
i. Reduces the elapsed time from hospital admission to
delivery
ii. Reduces the costs of induction of labour
iii. Improves women's experience of induction of labour
iv. Does not increase operative delivery rates
Women scheduled for induction of labour at term, and
who require pre-induction cervical ripening will be
invited to participate in the study. Participants will be ran-
domised into an active (IMN) or a control (placebo)
group and asked to self-administer either IMN 40 mg, or
a placebo, each vaginally, at 48 hours, 32 hours and 16
hours before scheduled admission. After admission to
hospital, treatment will revert to the usual induction of
labour protocol whereby prostaglandins are given until
cervical ripening is achieved, and fetal membrane rupture
is performed thereafter, followed by syntocinon if con-
tractions do not start spontaneously. Data on the outcome
measures listed below will be collected and compared in
the two groups.
Trial design
IMOP is a double blind, randomised, placebo controlled
trial in a single clinical setting. Active and placebo treat-
ment will be allocated in a 1:1 ratio. The primary outcome
measures are the effect of outpatient pre-induction cervi-
cal ripening with IMN on:
i. The elapsed time from hospital admission to delivery
(defined as the time from admission to inpatient induc-
tion or admission in labour to delivery – either vaginally
or by caeserean section)
ii. The costs of induction of labour
iii. Women's experience of induction of labour (maternal
satisfaction)
iv. Operative delivery rates
Setting
The study will be carried out in a large UK NHS teaching
hospital (Princess Royal Maternity, Glasgow).BMC Pregnancy and Childbirth 2006, 6:25 http://www.biomedcentral.com/1471-2393/6/25
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Participants
Inclusion criteria
Women scheduled for induction of labour will be invited
to participate in the study. The rationale for induction of
labour in the majority (but not all) of these women will
be post-dates pregnancy. The hospital protocol is to offer
induction of labour after 40 weeks and 10 days gestation,
and in the PRIM study, "post dates" was the principal rea-
son for induction of labour in over 70% of subjects. The
other inclusion criteria will be as follows:
▪ Bishop Score ≤ 6
▪ Singleton pregnancy
▪ Nulliparity
▪ ≥37 completed weeks of gestation
▪ Willing to self administer vaginal tablets
Exclusion criteria
▪ fetal compromise of sufficient severity that daily fetal
monitoring is scheduled.
Recruitment and consent
Subjects will not be formally recruited to the study until
the decision to induce labour is made. Potential subjects
will be informed about the trial and given written infor-
mation in the third trimester. Those women who wish to
participate and who understand the nature of the trial will
be asked to complete and sign two copies of the consent
form. Those women who do not wish to participate, or
who are ineligible will be asked (verbally) for permission
to record some basic data so that the generalisability of
the trial can be subsequently assessed.
Women scheduled for induction of labour at term will be
recruited and randomised at an antenatal visit by the clin-
ical research fellow, up to seven days prior to scheduled
admission for induction of labour. A vaginal examination
will not be repeated if one has been done and each of the
components of the Bishop score documented within 7
days of anticipated start of outpatient treatment. Women
willing to participate in the study will be given their ran-
domised study medication (either IMN tablets or pla-
cebo) at this visit, with instructions to self-administer the
tablets vaginally starting 48 hours prior to the scheduled
time of admission for induction of labour.
Randomisation
Randomisation to IMN or placebo will be in the ratio 1:1,
using randomised permuted blocks. The randomisation
schedule will be generated by the Study Data Centre at the
Centre for Healthcare Randomised Trials (CHaRT) at
Aberdeen University. The randomisation schedule will be
used by the Clinical Trials section of the pharmacy at the
Western Infirmary, Glasgow, to make up treatment packs
(either active or placebo) for each patient, each labelled
with the relevant unique study number. Active and pla-
cebo treatments will otherwise appear identical, so that
this will be a double blind study. A copy of the randomi-
sation schedule will be held at the Clinical Trials Phar-
macy at the Western Infirmary, and at CHaRT only. None
of the investigators will have access to the schedule until
completion of the study.
Within one hour after recruitment of each subject, the
pack number for the subject will be allocated by phone
call to the automated telephone randomisation service
located at CHaRT in Aberdeen.
Cessation of randomised treatment
The following will be indications for early cessation of
treatment
￿ Admission in labour
￿ Fetal membrane rupture
￿ Bleeding
The general practitioner and referring obstetrician will be
informed. The clinical research fellow will still collect out-
come data from women who have stopped taking their
study medication, unless the participant asks that her data
are not collected. Women who are admitted in labour,
women who experience spontaneous membrane rupture
and those who experience antepartum haemorrhage will
be asked not to take any more doses of study drug, but will
still be followed up. Women in whom fetal membranes
rupture after taking study medication will be asked to
come into the hospital for assessment. They will normally
be offered the option of immediate augmentation with
syntocinon, or delaying augmentation with syntocinon
until the next morning, depending on their preference.
In the event of a participant deciding to stop their medica-
tion themselves, or if cessation is recommended by the
supervising obstetrician, the clinical research fellow will
complete the withdrawal CRF. The clinical research fellow
will also inform the hospital pharmacy, and return any
unused medication. The general practitioner and referring
obstetrician will be informed.
Interventions
The intervention is one tablet inserted vaginally on three
occasions every 16 hours. In the experimental (IMN)
group, a 40 mg IMN tablet will be self-administered vagi-
nally by the patient at home 48, 32 and 16 hours beforeBMC Pregnancy and Childbirth 2006, 6:25 http://www.biomedcentral.com/1471-2393/6/25
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scheduled admission for induction of labour. In the con-
trol group, a placebo tablet, with an identical appearance
to that of IMN, will be self-administered vaginally by the
patient at home 48, 32 and 16 hours before scheduled
admission for induction of labour.
Rationale for dosage
IMN will be given in a dose of 40 mg. Previous studies
have shown that this dose is effective in inducing cervical
ripening both in the first trimester [8,9] and at term [11]
(PRIM) with no clinically significant effects on maternal
haemodynamics [10] and without unacceptable side
effects (PRIM) [11].
Rationale for dosage intervals
We have opted for a 16 hour dosage interval. Our previous
studies suggest that systemic absorption of IMN from vag-
inally administered tablets is slow [31], thus a short dos-
age interval might lead to accumulating serum levels of
drug. In the PRIM study, we gave a repeated dose of IMN
after 16 hours. Haemodynamic and symptomatic side
effects after the second dose of IMN were, if anything, less
than after the first, suggesting that a 16 hour treatment
interval is not associated with unacceptable systemic lev-
els of drug.
Rationale for duration of treatment
We have opted to give IMN for 48 hours prior to admis-
sion. We anticipate that the ripening effects of IMN will
continue after the first 24 hours, so that the cervix might
be fully ripened by 48 hours after treatment.
With the exception of trial medication, subjects will nor-
mally be managed according to the induction of labour
protocol. Thus, once a subject is admitted after trial med-
ication, she will be managed according to the normal pro-
tocol, ignoring the use of the trial medication.
Outcomes
Data on the primary and secondary outcomes listed below
will be recorded.
Primary
i. Elapsed time interval from hospital admission to deliv-
ery (defined as the time from admission for inpatient
induction or admission in labour to delivery – either vag-
inally or by caesarean section)
ii. Costs to the health service of induction of labour
iii. Women's experience of induction of labour
Secondary
iv. Primary clinical outcome (elapsed time from admis-
sion to delivery) for the subgroup of women who deliver
vaginally
v. Operative delivery rates
vi. Incidence of unscheduled admission for reasons other
than labour commencing
vii. Duration and frequency of neonatal admissions to
special care
viii. Incidence of adverse maternal and fetal outcomes
such as uterine hypercontractility, postpartum haemor-
rhage (maternal outcomes) and meconium stained liq-
uor, five minute Apgar of less than seven (fetal outcomes)
ix. Length of labour
x. Oxytocin augmentation rates
xi. Epidural usage
xii. Proportion with unfavourable cervix at 24 hours after
admission
xiii. Requirement for additional inpatient cervical ripen-
ing agent
Collection of outcome data
Clinical data
Outcomes i, and iv – xiii will be recorded by the attending
midwifery staff and the clinical research fellow onto a
dedicated Case Report Form which will be placed in the
case notes of each participating subject. Data will be col-
lected on the health service resources used in the treat-
ment of each woman and infant during the period
between randomisation and hospital discharge to deter-
mine outcome ii. The trial data collection forms will
record the duration and intensity of maternal and neona-
tal care, based on standard criteria for level of care, as well
as profile maternal and neonatal complications. The start
of labour will be defined as the start of regular uterine
contractions 3 in 10 (mild to moderate in intensity), with
a cervical dilation equal to or greater than 3 cm. Compli-
ance will be assessed, as far as possible, by asking subjects
to complete a diary card indicating when they took study
medication.
Collection of health cost data
Observational research will also be required at the Prin-
cess Royal Maternity Hospital, to provide details of the
resources and staff inputs required for the induction of
labour, as well as staff time, tests, procedures, drugs andBMC Pregnancy and Childbirth 2006, 6:25 http://www.biomedcentral.com/1471-2393/6/25
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equipment entailed by complications. Tick charts will be
completed by health professionals caring for all women
and infants in the trial, to document the key resource and
staff inputs not recorded by the trial data collection forms.
A similar approach to documenting health service
resource inputs has successfully been applied to other
National Perinatal Epidemiology Unit economic evalua-
tions conducted alongside clinical trials [32].
Unit costs for each resource item will be calculated by
sending the finance department at the Princess Royal
Maternity Hospital a detailed questionnaire requesting
cost data for the main resource categories of drugs, dispos-
ables, consumables, surgical procedures, equipment, staff
and overheads, and then apportioning these to different
categories of patient using a 'top-down' methodology. The
finance department will be visited on several occasions in
order to validate the cost data provided. If required, addi-
tional cost data will be collected from secondary sources.
These will be obtained towards the end of the trial period
to ensure that the costs are as current as possible for the
final analysis.
Collection of maternal satisfaction/acceptability data
Outcome iii, women's experience of induction of labour,
will be drawn from two approaches. First, all women will
be asked to complete a short questionnaire one hour
before taking IMN using simple visual analogue scales for
pain and anxiety. Baseline anxiety status will be assessed
using the Eysenck anxiety scale. Women will be asked to
note other symptoms and comments. We will ask women
to complete further questionnaires after each 16 hour
treatment period. Women will be given a stamped
addressed envelope to send the completed forms to the
social science researcher after delivery. All women will
also be asked to complete a short follow-up questionnaire
after delivery to ascertain satisfaction with cervical ripen-
ing, labour and delivery, pain scores and comments on
the labour (e.g. duration). Women will be given the post
delivery questionnaire at the hospital for completion, and
asked to hand it in prior to discharge from hospital. In
addition to the questionnaire strategies described above, a
consecutive series of women recruited in the second year
of the study will be approached for consent to being inter-
viewed three weeks after delivery. We aim to interview 20
women in total. The interview will collect in-depth
responses to the situation of women being at home dur-
ing cervical ripening, including views on whether they felt
in control of the situation, how easy it was to administer
the tablet, whether they managed to administer the tablet
at the prescribed intervals and any other positive or nega-
tive feelings.
Collection of health professionals attitudinal data
As it is anticipated that cervical ripening at home may
change the workload within the labour suites, midwives
working in the Unit will be asked to take part in focus
groups. (The use of focus groups have previously been
found to be valuable in studying organisational change
[33]). It is anticipated that around five focus groups, each
of six midwives and lasting one hour will be needed. Staff
will be recruited from those working in the obstetric unit
at the PRM. Those expressing interest will be given an
information sheet about the study and asked to complete
a consent form. The topic guide for the focus group will be
generated by the social science researcher. The purpose of
the focus groups will be to discuss any perceived changes
in ward throughput, management, and organisation. The
focus groups will also ascertain whether staff perceive
there are any benefits or disadvantages to women having
outpatient pre-induction cervical ripening, and explore




Three hundred women will be recruited, of whom about
150 will be in the experimental and about 150 will be in
the control (placebo) group. The primary outcome on
which this study is powered is the time interval from hos-
pital admission to delivery. In women undergoing induc-
tion of labour with Bishop scores 0–4 and 5–8, the mean
(SD) induction to delivery intervals are 19.65 (10.75)
hours and 15.17 (6.80) hours respectively (J Norman,
data on file). With 150 women in each of the IMN and
placebo groups (300 in total) the study has 96% power at
a 5% level of significance to detect a difference in mean
time from admission to delivery of 4 hours, assuming a
common standard deviation of 9 hours, using a two sam-
ple two sided t-test.
Women's experience of induction of labour will be
explored qualitatively and quantitatively. As in the PRIM
study, we will ask women to indicate satisfaction with the
ripening process on a visual analogue scale. Assuming
similar results in the PRIM study (that those pretreated
with IMN will give a mean (SD) score of satisfaction of 7.0
and those who have prostaglandins only as the active rip-
ening agent will give a mean (SD) score of satisfaction of
5.8, with a common standard deviation of 3.0, the study
has 93% power to detect a significant difference in satis-
faction rates, given a sample size of 150 in each group. Sta-
tistical power of 90% or above (at the 5% significance
level) is maintained if the number of evaluable patients in
each group is 133 or greater.BMC Pregnancy and Childbirth 2006, 6:25 http://www.biomedcentral.com/1471-2393/6/25
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Loss to follow up
We do not anticipate any appreciable loss to follow up i.e.
women failing to return usable data on the primary out-
come.
Failure to initiate on randomised study medication
Those women who go into spontaneous labour after
recruitment, but before starting trial drug, and those
women who withdraw from the study at this stage will (if
they consent to continuing use of their data) be included
in the primary analysis, but excluded from a subsequent
secondary analysis.
Since the treatment is self administered, there may be sub-
optimal delivery of the assigned treatment, which may
lead to a dilution of the anticipated treatment effect. For
example, if 1 in 8 (or 12.5%) of the IMN women failed to
properly administer the dose, the 4 hour treatment differ-
ence would be reduced to 3 hrs and 30 minutes. The study
would still have 93% power to detect such a difference,
and 81% power if this proportion of women rose to 1 in
4 (or 25%).
Statistical analysis ground rules
The primary endpoint of time from admission to delivery
will be compared between the two groups using a two
sample two sided t-test, and then adjusted for covariates
that are pre-specified as important using a linear model.
The analysis will be performed at the conclusion of the
study. Analysis of secondary outcomes will be using t-tests
(or Wilcoxon tests) or chi-squared tests as appropriate to
the distribution of the data, again with adjustment for
covariates using appropriate generalised linear models.
All statistical analyses will be fully specified in a Statistical
Analysis Plan, which will be signed off before the treat-
ment codes are broken. All primary analyses will be
according to the intention to treat principle. No interim
analyses will be performed, other than those requested by
the Data Monitoring committee. The results of these
interim analyses, and/or any other unblinded data will
not be revealed to the investigators or the Trial Steering
Committee until after the study is complete.
Analysis of the questionnaire data will be carried out
using SPSS and analysis of variance. Interviews and focus
groups will be coded and analysed using a computer pack-
age (ATLAS Ti) used to facilitate analysis of qualitative
data for emergence of salient themes.
A prospective economic evaluation will be conducted
alongside the randomised controlled trial to estimate the
cost-effectiveness of outpatient cervical ripening with
IMN prior to induction of labour. The cost differences
between the two groups, the IMN and placebo groups,
will be measured, valued and combined with the clinical
effectiveness data from the trial. The economic evaluation
will incorporate data from all subjects recruited into the
trial. The valuation of all resource inputs will be consistent
with the notion of opportunity cost.
The economic evaluation will be conducted from a health
service perspective and will take two forms; (i) an overall
cost analysis and (ii) an incremental cost-effectiveness
analysis, which will be expressed in several forms, for
example, incremental cost per operative delivery pre-
vented [34]. All analyses will be conducted on the basis of
intention to treat. Outcomes and costs for the experimen-
tal and control groups will be compared using relative
risks and 95% confidence intervals for dichotomous vari-
ables, Mann-Whitney-U tests for ordinal variables, and
Student's t-tests for interval variables where parametric
assumptions are met. Fieller's theorem will be used to cal-
culate 95% confidence intervals for incremental cost-
effectiveness ratios [35]. In the absence of stochastic data
for all variables, a series of multi-way sensitivity analyses
will be undertaken to explore the implications of uncer-
tainty on the base-case incremental cost-effectiveness
ratios. In addition, cost-effectiveness acceptability curves
will be constructed using the net benefits approach [36].
All analyses will be performed with a microcomputer
using Statistical Package for the Social Sciences (SPSS)
software, version 11.5.
Confidentiality and data security
Once a participant has agreed to join the trial, the clinical
research fellow will record, on a standard form, identify-
ing and contact information to be kept locally.
￿ Full name, address, telephone number (home and
mobile)
￿ Date of birth
￿ NHS hospital number and CHI number (if available)
￿ General practitioner and hospital consultant name and
address
￿ Unique trial number (to be issued by CHaRT after
recruitment)
This information will not be sent to the trial office, but
will be kept locally (in a locked cabinet) by the clinical
research fellow as a linkage between the trial number and
the patient's identity. The following information will be
sent to the trial office as participant identifiers.
￿ Initials, date of birth, hospital number, Bishop scoreBMC Pregnancy and Childbirth 2006, 6:25 http://www.biomedcentral.com/1471-2393/6/25
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￿ Unique trial number (to be issued by CHART)
The patient's case notes will be regarded as source data/
documents. The local investigators (grantholders and
clinical research fellow appointed to the study) will have
access to the source data and will extract the data required
for the CRF. A trial manager from CHaRT (Centre for
Healthcare Randomised Trials) will also access source
data to ensure quality control. No patient identifying
information will leave the hospital.
The clinical research fellow will enter study CRFs onto the
study database held by CHaRT in Aberdeen within one
month of subject completion of the trial (defined as dis-
charge of mother and baby from hospital) via the IMOP
study web portal. CHART staff will work closely with the
clinical research fellow to secure as complete and accurate
data as possible. Extensive range and consistency check
will further enhance the quality of the data.
CHaRT will make site visits to the study centre (PRM) to
ensure quality control and quality assurance. A random
sample of patient records will be reviewed to ensure accu-
rate transcription onto the CRFs. CHaRT will review
incoming CRFs and ask the clinical research fellow to
complete missing data, and to clarify anomalies.
Ethics and other regulatory issues
The study has MREC approval from the West Glasgow
Ethics Committee 1 (04/S0703/35) (see additional file no
1) and LREC approval from Glasgow Royal Infirmary/
Princess Royal Maternity. The MREC, will be informed of
amendments to the protocol or patient information. The
LREC will also be informed of these amendments at
MREC's request. The study had a DDX exemption from
the MHRA (13608), which was subsequently "rolled
over" into a CTA. The study has been registered on the
EUDRAct database 2004-000995-15.
Data Monitoring Committee
A Data Monitoring Committee (DMC) will be estab-
lished. This will consist of two obstetricians and a statisti-
cian and will be independent of the trial organisers. The
DMC will advise the Steering Committee if, in its view,
one or more of the randomised comparisons in the trial
has provided both (a) proof beyond reasonable doubt
that for all or some types of patients one particular type of
intervention is clearly indicated in terms of a reduction in
the induction to delivery interval, (or clearly contraindi-
cated because of a net increase in induction to delivery
interval or other adverse events), and (b) evidence that
might reasonably be expected to influence materially the
care of women having induction of labour by clinicians
who know the results of this and comparable trials. The
Steering Committee will then decide whether or not to
modify intake to the trial. Unless this happens, however,
the steering committee, clinical collaborators, and trial
office staff (except those who supply the confidential
analyses) will remain ignorant of the interim results.
(Note that appropriate criteria for proof beyond reasona-
ble doubt cannot be specified precisely. A difference of at
least three standard deviations in the interim analysis of a
major endpoint may be needed to justify halting, or mod-
ifying, such a study prematurely. If this criterion were to
be adopted, it would have the practical advantage that the
exact number of interim analyses would be of little impor-
tance, and so no fixed schedule is proposed) [37].
Interim analysis of some of the clinical outcomes (e.g. cae-
sarean section rate, admission to hospital during ripening
phase for reasons other than onset of labour) will be per-
formed by the Data Monitoring Committee after about
180 women have been recruited. Criteria for advising the
early termination of the study for safety reasons or for
overwhelming evidence of benefit will be determined
before any unblinded data is seen, and documented in the
Minutes of the meeting of the DMC. There are no plans to
stop the study early for futility. Assuming the termination
criteria are not satisfied, the results will not be revealed to
the investigators or participants, and no further analyses
will be performed until data acquisition is complete.
Funding and sponsorship
The study is funded by a research grant from the Charity
Wellbeing at the Royal College of Obstetricians and
Gynaecologists (see additional file 2). The study "spon-
sors" (as defined by the EU directive) are Glasgow Univer-
sity and North Glasgow University Hospital Division. The
funder of the study has had no input into protocol design.
Study website
A fuller version of the study protocol is available at the
study website [38].
Discussion
We believe that outpatient IMN will reduce the time from
hospital admission to delivery, reduce the costs of induc-
tion of labour and improve women's experience of induc-
tion of labour (with no increase in operative delivery
rates). This trial will determine whether these hypotheses
are correct. If so, we anticipate that women undergoing
induction of labour in the UK and in other countries
worldwide could use outpatient IMN as soon as the find-
ing are published, since the formulation of IMN we plan
to investigate in this study is cheap and widely available.
Abbreviations
IMN – Isosorbide mononitrateBMC Pregnancy and Childbirth 2006, 6:25 http://www.biomedcentral.com/1471-2393/6/25
Page 9 of 10
(page number not for citation purposes)
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
FM, JN, SP, MR, IAG, IO, and JEN were all responsible for
the conception and design of the study. SB, FM, JN, SP,
MR, IAG, IO, and JEN were all responsible for drafting the
protocol, and are involved in the development and imple-
mentation of the study. All authors have read and given
approval of the final manuscript.
Acknowledgements
This study is funded by a Clinical trials grant from the UK charity Wellbeing 
(ref no CT 2004). We are grateful to Dr Andrew Thomson for Chairing the 
Trial Steering Committee, and to Dr Philip Owen for Chairing the Data and 
Safety Monitoring Committee.
References
1. Royal College of Obstetricians and Gynaecologists: Induction of labour
RCOG: London; 2001. 
2. Stitely ML, Browning J, Fowler M, Gendron RT, Gherman RB: Out-
patient cervical ripening with intravaginal misoprostol.
Obstet Gynecol 2000, 96(5 Pt 1):684-8.
3. McKenna DS, Costa SW, Samuels P: Prostaglandin E2 cervical
ripening without subsequent induction of labor.  Obstet Gynecol
1999, 94(1):11-4.
4. Farmer KC, Schwartz WJ 3rd, Rayburn WF, Turnbull G: A cost-
minimization analysis of intracervical prostaglandin E2 for
cervical ripening in an outpatient versus inpatient setting.
Clin Ther 1996, 18(4):747-56. discussion 702
5. Biem SR, Turnell RW, Olatunbosun O, Tauh M, Biem HJ: A rand-
omized controlled trial of outpatient versus inpatient labour
induction with vaginal controlled-release prostaglandin-E2:
effectiveness and satisfaction.  J Obstet Gynaecol Can 2003,
25(1):23-31.
6. Rayburn W, Tassone S, Pearman C: Is cervidil appropriate for
outpatient cervical ripening.  Obstet Gynecol 2000, 95:S63.
7. Voss DH, Cumminsky KC, Cook VD, Nethers MS, Spinnato JA, Gall
SA: Effect of three concentrations of intracervical prostaglan-
din E2 gel for cervical ripening.  J Matern Fetal Med 1996,
5(4):186-93.
8. Thomson A, Lunan C, Cameron A, Cameron I, Greer I, Norman J:
Nitric oxide donors induce ripening of the human uterine
cervix: a randomised controlled trial.  British Journal of Obstetrics
and Gynaecology 1997, 104:1054-1057.
9. Thomson AJ, Lunan CB, Ledingham M, Howat RC, Cameron IT,
Greer IA, Norman JE: Randomised trial of nitric oxide donor
versus prostaglandin for cervical ripening before first-tri-
mester termination of pregnancy.  Lancet 1998,
352(9134):1093-6.
10. Nicoll A, Mackenzie F, Greer I, Norman J: Vaginal application of
the nitric oxide donor isosorbide mononitrate for pre-induc-
tion cervical ripening: a randomised controlled trial to deter-
mine effects on maternal and fetal haemodynamics.  American
Journal of Obstetrics and Gynecology 2001, 184:958-964.
11. Osman I, MacKenzie F, Norrie J, Murray HM, Greer IA, Norman JE:
The "PRIM" study: a randomized comparison of prostaglan-
din E2 gel with the nitric oxide donor isosorbide mononi-
trate for cervical ripening before the induction of labor at
term.  Am J Obstet Gynecol 2006, 194(4):1012-21.
12. Ekerhovd E, Bullarbo M, Andersch B, Norstrom A: Vaginal admin-
istration of the nitric oxide donor isosorbide mononitrate
for cervical ripening at term: a randomized controlled study.
Am J Obstet Gynecol 2003, 189(6):1692-7.
13. Tassone SA, Pearman CR, Rayburn WF: Outpatient cervical rip-
ening using a sustained-release prostaglandin E2 vaginal
insert.  J Reprod Med 2001, 46(6):599-600.
14. Sanchez-Ramos L, Kaunitz AM: Outpatient cervical ripening with
intravaginal misoprostol.  Obstet Gynecol 2001, 97(2):325-6.
15. Rayburn W, Lucas M, Gittens L, Goodwin TM, Baxi L, Gall S, Mostello
D, Heyl P: Attempted vaginal birth after cesarean section: a
multicenter comparison of outpatient prostaglandin E(2) gel
with expectant management.  Prim Care Update Ob Gyns 1998,
5(4):182-183.
16. Rayburn W, Gosen R, Ramadei C, Woods R, Scott J Jr: Outpatient
cervical ripening with prostaglandin E2 gel in uncomplicated
postdate pregnancies.  Am J Obstet Gynecol 1988, 158(6 Pt
1):1417-23.
17. Neale E, Pachulski A, Whiterod S, McGuinness E, Gallagher N, Wal-
lace R: Outpatient cervical ripening prior to induction of
labour.  J Obstet Gynaecol 2002, 22(6):634-5.
18. Larmon JE, Magann EF, Dickerson GA, Morrison JC: Outpatient
cervical ripening with prostaglandin E2 and estradiol.  J
Matern Fetal Neonatal Med 2002, 11(2):113-7.
19. Incerpi MH, Fassett MJ, Kjos SL, Tran SH, Wing DA: Vaginally
administered misoprostol for outpatient cervical ripening in
pregnancies complicated by diabetes mellitus.  Am J Obstet
Gynecol 2001, 185(4):916-9.
20. Evans MI, Dougan MB, Moawad AH, Evans WJ, Bryant-Greenwood
GD, Greenwood FC: Ripening of the human cervix with por-
cine ovarian relaxin.  Am J Obstet Gynecol 1983, 147(4):410-4.
21. Elliott JP, Clewell WH, Radin TG: Intracervical prostaglandin E2
gel. Safety for outpatient cervical ripening before induction
of labor.  J Reprod Med 1992, 37(8):713-6.
22. Sawai SK, O'Brien WF, Mastrogiannis DS, Krammer J, Mastry MG,
Porter GW: Patient-administered outpatient intravaginal
prostaglandin E2 suppositories in post-date pregnancies: a
double-blind, randomized, placebo-controlled study.  Obstet
Gynecol 1994, 84(5):807-10.
23. Sawai SK, Williams MC, O'Brien WF, Angel JL, Mastrogiannis DS,
Johnson L: Sequential outpatient application of intravaginal
prostaglandin E2 gel in the management of postdates preg-
nancies.  Obstet Gynecol 1991, 78(1):19-23.
24. Sciscione AC, Muench M, Pollock M, Jenkins TM, Tildon-Burton J,
Colmorgen GH: Transcervical Foley catheter for preinduction
cervical ripening in an outpatient versus inpatient setting.
Obstet Gynecol 2001, 98(5 Pt 1):751-6.
25. Smith MA, Swan L, Caruthers BS, Heaton C: Outpatient use of
prostaglandin gel for ripening of the cervix and induction of
labor.  J Fam Pract 1990, 30(6):656-62. discussion 662–4
26. Upadhyaya NB, Childs KD, Neiger R, Caudle MR: Ambulatory cer-
vical ripening in term pregnancy.  J Reprod Med 1999,
44(4):363-6.
27. Chanrachakul B, Herabutya Y, Punyavachira P: Randomised com-
parison of glyceryl trinitrate and prostglandin E2 for cervical
ripening at term.  Obstetrics and Gynecology 2000, 96:549-553.
28. Chanrachakul B, Herabutya Y, Punyavachira P: Randomized trial of
isosorbide mononitrate versus misoprostol for cervical rip-
ening at term.  Int J Gynaecol Obstet 2002, 78(2):139-45.
29. Hofmeyr GJ, Gulmezoglu AM: Vaginal misoprostol for cervical
ripening and induction of labour.  Cochrane Database Syst Rev
2003:CD000941.
30. Schaff EA, Stadalius LS, Eisinger SH, Franks P: Vaginal misoprostol
administered at home after mifepristone (RU486) for abor-
tion.  J Fam Pract 1997, 44(4):353-60.
31. Bates CD, Nicoll AE, Mullen AB, Mackenzie F, Thomson AJ, Norman
JE:  Serum profile of isosorbide mononitrate after vaginal
administration in the third trimester.  Bjog 2003, 110(1):64-7.
32. Roberts TE: Economic evaluation and randomised controlled
trial of extracorporeal membrane oxygenation: UK collabo-
rative trial. The Extracorporeal Membrane Oxygenation
Economics Working Group.  Bmj 1998, 317(7163):911-5. discus-
sion 915–6
33. Barbour R: Are focus groups an appropriate tool for studying
organisational change.  In Developing focus group research Edited by:
Barbour R, Kitzinger J. Sage: London; 1999. 
34. Drummond MF, O'Brien B, Stoddart G, Torrance G: Methods for the
economic evaluation of health care programmes 2nd edition. Oxford:
OUP; 1999. 
35. Willan AR, O'Brien BJ: Confidence intervals for cost-effective-
ness ratios: an application of Fieller's theorem.  Health Econ
1996, 5(4):297-305.
36. Cost effectiveness analysis of improved blood pressure con-
trol in hypertensive patients with type 2 diabetes: UKPDSPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pregnancy and Childbirth 2006, 6:25 http://www.biomedcentral.com/1471-2393/6/25
Page 10 of 10
(page number not for citation purposes)
40. UK Prospective Diabetes Study Group.  Bmj 1998,
317(7160):720-6.
37. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Man-
tel N, McPherson K, Peto J, Smith PG: Design and analysis of ran-
domized clinical trials requiring prolonged observation of
each patient. I. Introduction and design.  Br J Cancer 1976,
34(6):585-612.
38. Centre for Health Care and Randomised Trials: IMOP study  [https://
www.charttrials.abdn.ac.uk/imop/study_site/index.php].
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2393/6/25/prepub